Skip to main content

Harvard Medical School to Use High Throughput Genomics' qNPA Technology

NEW YORK (GenomeWeb News) – Harvard Medical School researchers will use High Throughput Genomics’ technology to develop an assay that can measure the expression of miRNA precursors, mature microRNAs, and regulated RNA.
 
Tucson, Ariz.-based HTG said today that it will collaborate with the Harvard Catalyst Laboratory for Innovative Translational Technologies at Harvard Medical School to create the biogenesis assay.
 
Under the agreement, the lab will use HTG’s quantitative Nuclease Protection Assay technology, which the company said allows researchers to “test any sample, including fixed tissues, without RNA extraction or target amplification.” The qNPA technology is used to carry out quantitative, multiplexed gene-based drug programs, including target validation, HTS lead optimization, metabolism, toxicology, and clinical development.
 
Financial terms of the agreement were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.